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Liver synthetic and metabolic function can only be optimised by the growth of cells within a 
supportive liver matrix. This can be achieved by the utilisation of decellularised human liver tissue. 
Here we demonstrate complete decellularization of whole human liver and lobes to form an 
extracellular matrix scaffold with a preserved architecture. Decellularized human liver cubic scaffolds 
were repopulated for up to 21 days using human cell lines hepatic stellate cells (LX2), hepatocellular 
carcinoma (Sk-Hep-1) and hepatoblastoma (HepG2), with excellent viability, motility and proliferation 
and remodelling of the extracellular matrix. Biocompatibility was demonstrated by either omental or 
subcutaneous xenotransplantation of liver scaffold cubes (5 × 5 × 5 mm) into immune competent mice 
resulting in absent foreign body responses. We demonstrate decellularization of human liver and 
repopulation with derived human liver cells. This is a key advance in bioartificial liver development.
Deaths from liver disease are increasing worldwide. According to the World Health Organisation, the 
total deaths caused by cirrhosis and liver cancer have increased by 50 million/year since 19901. In the 
UK, the number of deaths from cirrhosis in those < 65 years have increased ~6 fold in the last 30 years2. 
At present, liver transplantation is the only successful treatment for patients with end stage liver disease. 
However, 20% of patients die on the waiting list due to a shortage of organ donors3. To expand the sup-
ply of livers available for transplantation, transplant surgeons and physicians have explored several new 
approaches including split liver transplants, living-related partial donor procedures4 and the increasing 
use of “marginal” organs such as older donors, steatotic livers, non-heart-beating donors, donors with 
viral hepatitis, and donors with non-metastatic malignancy5. Despite these medical and surgical develop-
ments, it is unlikely that the availability of good liver grafts will ever be sufficient to meet the increasing 
demand of patients with end stage liver disease.
Alternatives to liver transplantation such as liver support systems, including bioartificial livers, and 
hepatocyte transplantation have been extensively explored but none adopted in clinical practice6–11.
In the UK, over 40% of the livers offered for transplantation are declined because of prolonged 
ischemic time or co-morbidities judged beyond marginal criteria12. This provides us with a major oppor-
tunity to explore alternative uses of human livers found to be unsuitable for transplantation following 
organ retrieval. In particular, while cellular viability is easily compromised, extracellular matrix (ECM) 
is better maintained in the discarded livers and it may be used as scaffold in which to grow normal 
human liver cells and recreate functional human liver tissue in vitro. Such cells could be obtained from 
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recipient’s hepatocytes obtained from induced pluripotent stem (iPS) cells and thus avoid the need for 
immunosuppression. Alternatively, liver cells could be obtained from human livers unsuitable for liver 
transplantation or following liver resection. If successful, ECM liver bioengineering has the potential 
to be used not only as an alternative to whole organ transplantation but also for toxicity testing during 
preclinical drug development13 and for more stringent liver disease modelling.
Several studies have reported the decellularization of liver tissue obtained from animals14–17. The 
resulting 3-dimensional ECM scaffolds have been shown to provide an excellent environment for the 
in vitro growth of multiple liver cell types retaining excellent functionality18,19. Notably, in 2010, the 
repopulation of an acellular rat liver scaffold with 50 million mature rat hepatocytes was achieved by 
cell perfusion via the portal vein. Importantly, hepatocytes migrated beyond the matrix barrier to reach 
the decellularized sinusoidal spaces20. In 2012, a further step onward was made with the repopulation 
of a pig liver scaffold with human foetal hepatocytes and stem cells21. However, the decellularization 
and repopulation of a human liver ECM scaffold with human derived liver cells has not been reported.
The aim of this study was firstly to demonstrate the feasibility of an innovative protocol for the 
decellularization of a single lobe or of the whole human liver and to fully assess the quality and the 
in vivo biocompatibility of the resulting liver ECM scaffold. Secondly, to assess the capability of different 
types of human liver cells to repopulate hepatic ECM scaffolds (Fig.  1). Altogether the results of this 
study provide clear proof of concept data supporting the development of a bio-artificial liver tissue by 
employing decellularized human ECM liver scaffolds, thus opening, in general, more new possibilities in 
regenerative medicine for the use of donor human livers currently unsuitable for transplantation.
Results
Decellularization of human segmental lobes or whole liver. Decellularization of the left lobe 
of the liver (segments 1-2-3) was completed within 14 days of perfusion, and within 6 weeks for the 
whole human liver (Fig. 2a–c). During and following decellularization the whole liver or lobes gradually 
became increasingly translucent with the dissolution of cells (Fig. 2a–c). The decellularization protocol, 
based on a retrograde perfusion through the hepatic venous system and inferior vena cava, was charac-
terized by the combination of five different Cell-Damaging Factors (5CDFs): i) mechanical cell damaging 
(freezing/thawing) to favor cell destruction; ii) isotonic stress to allow cell lysis; iii) enzymes to allow cell 
detachment; iv) action of detergents to remove debris; and v) flow shear stress to allow the penetration 
into the hepatic sinusoid leading to the detachment of cells and debris. Histological evaluation by H&E 
staining showed no evidence of cell bodies or cellular material including nuclei in the decellularized liver 
(Fig.  2d). In addition, the general liver tissue architecture appeared fully preserved as shown by Sirius 
Red staining for collagens (Fig. 2e) and Von Gieson staining for elastin (Fig. 2f).
The absence of cells in the ECM scaffold was confirmed by the absence of DNA material quantified 
by DNeasy Blood and Tissue kit (Fig. 2g). As already reported in other perfusion-decellularization pro-
tocols17,22,23, collagen content relative to wet weight was increased (p < 0.01; Fig. 2h), whereas elastin was 
decreased (p < 0.01) in the decellularized tissue when compared with fresh liver tissue (Fig. 2i).
Liver tissue scaffold characterisation. The expression and distribution of the extracellular matrix 
(ECM) of the decellularized liver (DL) scaffold was next analysed, comparing it with ECM of fresh 
human liver tissue (FL) by immunohistochemistry. This analysis showed that the expression and distribu-
tion of key ECM components, namely collagen type I (Fig. 3c,d), collagen type III (Fig. 3g,h), fibronectin 
(Fig.  3o,p) and collagen IV (Fig.  3k,l) were fully maintained when compared to that detected in FL. 
Importantly, the pattern of distribution of each ECM component within the DL confirmed the full pres-
ervation of the architectural organisation of the original liver tissue (FL).
Ultrastructural characterization of decellularized human liver. Scanning electron microscopy 
was used to evaluate the impact of decellularization on the 3D-architecture and micro-structure of the 
ECM (Fig. 4). The overall liver tissue micro-structure appeared maintained. Key architectural structures 
such as portal tracts were clearly recognised with their typical features and distribution within the scaffold 
(Fig. 4a, asterisk). The areas corresponding to the liver lobule were characterised by a three-dimensional 
network of connective tissue fibres arranged in a honeycomb-like structure (Fig. 4b). Most notably, the 
hepatocyte pocket was preserved and was surrounded by a thorough network of ECM proteins (Fig. 4c). 
Overall, these data confirm the preservation of the 3D liver microanatomy and ultrastructure following 
decellularization.
Interspecies bio-compatibility of decellularized human liver ECM scaffolds. Cubic fragments 
of ECM scaffold (5 × 5× 5 mm3 for a total volume of 125 mm3) were obtained by scalpel cleavage of 
the whole decellularized livers, and implanted into immunocompetent mice to evaluate the in vivo 
bio-compatibility in a xenotransplantation model. Liver ECM cubes were implanted either subcutane-
ously (n = 6) or into the omentum (n = 6), and evaluated at 7 and 21 days post-implantation. Clinical 
behaviour of animals and local signs of inflammation were closely monitored. Both subcutaneous and 
omental implanted liver scaffolds were evaluated macroscopically, histologically and immunohistochem-
ically for the presence of inflammatory reaction, foreign body responses and angiogenesis. During the 
period of observation, mice showed normal behaviour, without local signs of inflammation, implant 
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exposure, extrusion or death. Macroscopic examination at the time of enucleation showed healthy nor-
mal tissue around the implants, with no signs of inflammation, such as redness and swelling, or adverse 
tissue reactions around the implants, such as destruction of normal structures, at both subcutaneous and 
omental sites (Figs 5 and 6, panels a,e, respectively).
Histology was performed on formalin-fixed samples embedded in paraffin and sectioned at 4- μ m 
thickness. Representative sections were stained with haematoxylin and eosin and immunostained 
for alpha smooth muscle actin (alpha-SMA) and CD3. Histological analysis confirmed the absence 
of a foreign body reaction, and the absence of giant cells or granulomata within any of the samples. 
Polymorphonuclear cells and lymphocytes were observed at 7 days post-implantation, indicating a mild 
inflammatory response surrounding the implantation sites. Inflammatory cells were mostly seen in the 
Figure 1. Schematic study plan. Human liver unsuitable for transplantation is surgically processed in 
order to obtain an isolated left lobe or is used as a whole (a,b). Lobes or whole organs are cannulated 
and decellularized by retrograde perfusion (c). Once decellularization is completed, human liver scaffolds 
are dissected by scalpel cleavage to obtain liver cubes (d) as a 3D-platform for biocompatibility and 
bioengineering studies (e,f).
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Figure 2. Perfusion-decellularization of human liver. Macroscopic appearance of a decellularized left lobe 
showing preservation of the vascular tree (a), translucent color (b) and a complete human liver  
(c). Histological comparison (10X and 40X magnification, left panel and right panel, respectively) of fresh 
liver (FL) and decellularized liver (DL) by Hematoxylin and Eosin (H&E) (d), Sirius Red (SR) (e) and 
Elastin Von Gieson EVG (f) staining demonstrating removal of cells and preservation of collagen and 
elastin in DL. Scale bar for 10X magnification: 200 μ m and 40X: 50 μ m. DNA quantification demonstrated 
significant DNA reduction from 1425.23 ± 261.37 ng/mg in FL to 47.91 ± 5.82 ng/mg in DL (g). Collagen 
significantly increased from 5.860726 ± 1.417547 μ g/mg in FL to 90.85345 ± 14.16523 μ g/mg in DL 
scaffolds (h). Elastin quantification demonstrated a significant decrease from 34.56827 ± 5.102387 μ g/mg to 
7.073619 ± 0.434233 μ g/mg in in DL scaffolds (i).
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tissue around the implants (Figs  5 and 6, panels b,c). Immunohistochemistry indicated that infiltrat-
ing host cells were predominantly CD3+ T-cell lymphocytes (data not shown). By contrast, at 21 days 
post-implantation, reduced or no inflammatory infiltrate was observed around the implants (Figs 5 and 
6, panels f,g).
Immunohistochemistry for alpha-SMA revealed that alpha-SMA-negative, spindle-like cells, most 
likely representing fibroblasts, had infiltrated the implants after 21 days post-implantation (Figs  5 and 
6, panel h). On the other hand, positivity for alpha-SMA revealed the presence of abundant neo-vessels 
(mostly arterioles), initially close to the interface host tissue/human scaffold (7 days, Figs 5 and 6, panel 
d) and subsequently deeper within the scaffold (21 days, Figs 5 and 6, panel h), thus providing evidence 
for neovascularisation of the implant.
Re-population of decellularized human liver ECM scaffolds with human liver cell types. Human 
liver ECM cubes were incubated in complete medium overnight before seeding the scaffolds with LX2 
(a human hepatic stellate cell line), HepG2 (epithelial cells derived from hepatocellular carcinoma) or 
Sk-Hep-1 (endothelial cells, derived from highly invasive human adenocarcinoma) human cell types 
(Fig. 7a). Cells [2 × 106/50 μ L] were drawn up in a 0.5 ml insulin syringe and released drop by drop to 
finally cover the liver ECM cubes. Cubes incubated with the different cell types were evaluated after 7, 
14 and 21 days of in vitro static culture. H&E staining demonstrated the progressive engraftment of LX2 
cells into the scaffold over 21 days (Fig. 7b) with a diffuse presence of proliferative cells (Fig. 7c). Indeed, 
Figure 3. Expression and distribution of ECM proteins. Collagen I, III and IV staining in FL is seen as 
fine strands in the parenchymal space as well as around the blood vessels (a,b; e,f; I,j). Collagen I and III 
distribution was preserved following decellularization as demonstrated by a staining in both sinusoids and 
portal tracts in DL (c,d; g,h). Collagen IV (k,l) and fibronectin (o,p) staining showed a conserved meshwork 
in sinusoids and biliary ducts after decellularization. Scale bar for 20X magnification (left panel): 100 μ m and 
40X (right panel): 50 μ m.
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Figure 4. Ultrastructural characterisation of decellularized livers. Low magnification SEM image 
confirmed acellularity in the scaffolds and demonstrated preservation of the three-dimensional micro-
anatomy of the portal tract (arrow/asterisk) surrounded by a typical lobular structure (a). The parenchymal 
space appears characterised by connective tissue fibres arranged with a honeycomb-like pattern, clearly 
defining hepatocyte-free spaces (b). High magnification resolution demonstrates an exceptionally preserved 
three-dimensional meshwork of connective tissue fibres structuring the hepatocyte-free spaces (c). Scale bars 
for (a,b): 100 μ m and (c): 10 μ m.
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Figure 5. Interspecies biocompatibility: subcutaneous implantation. Human liver cubic scaffolds were 
implanted subcutaneously (n = 6) and evaluated at 7 and 21 days post-implantation. Polymorphonuclear 
cells and lymphocytes were observed at 7 days post-implantation, indicating a mild inflammatory response. 
Inflammatory cells were mostly seen in the tissue around the implants (b,c). By contrast, at 21 days 
post-implantation, little or no inflammatory infiltrate was observed around the implants (panels f,g). 
Immunohistochemistry for alpha-SMA showed SMA-negative, spindle-like cells, had infiltrated the implants 
after 21 days post-implantation (h) and revealed the presence of abundant neo-vessels (mostly arterioles) 
initially close to the interface host tissue/human scaffold (7 days, d, arrows) and subsequently deeper 
within the scaffold (21 days, h, arrows) indicating neovascularisation of the implant. Scale bars: for 10X 
magnification (b,f): 200 μ m, 20X (c,d,g,h): 100 μ m. Abbreviations: RS (recipient skin), LSC (liver scaffold) 
and RA (recipient adipose tissue).
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Figure 6. Interspecies biocompatibility: omental implantation. Human liver cubic scaffolds were 
implanted into the omentum (n = 6), and evaluated at 7 and 21 days post-implantation. As early as 
seven days after implantation, the implanted scaffold engrafted within the surrounding host abdominal 
structures: recipient liver (RL), recipient intestine (RI) and recipient pancreas (RP). Polymorphonuclear 
cells and lymphocytes were observed at 7 days post-implantation, indicating a mild inflammatory response. 
Inflammatory cells were mostly seen in the tissue around the implants (b,c). By contrast, at 21 days 
post-implantation, little or no inflammatory infiltrate was observed around the implants (panels f,g). 
Immunohistochemistry for alpha-SMA showed SMA-negative, spindle-like cells, had infiltrated the implants 
after 21 days post-implantation (h) and revealed the presence of abundant neo-vessels (mostly arterioles) 
initially close to the interface host tissue/human scaffold (7 days, d, arrows) and subsequently deeper 
within the scaffold (21 days, h, arrows) indicating neovascularisation of the implants. Scale bars: for 4X 
magnification (b,f): 500 μ m, 10X (c,g): 200 μ m and 20X (d,h): 100 μ m. Abbreviations: RL (recipient liver), 
RP (recipient pancreas), RI (recipient intestine), RO (recipient omentum) and LSC (liver scaffold).
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Figure 7. Recellularisation of human liver scaffolds. Human liver cubic scaffolds were incubated in 
complete medium overnight before seeding the scaffolds with LX2, HepG2 and Sk-Hep-1 cell lines  
(a). Bioengineered liver tissues were harvested at 7, 14 and 21 days. H&E (b,f,j) and Ki67 (c,g,k) staining 
showed that all cell types were able to repopulate liver scaffolds while still proliferating at 21 days. The total 
cell count in human liver scaffolds repopulated with LX2, HepG2 and Sk-Hep-1, increased significantly 
between 7 and 14–21 days (d,h,l, respectively). Scale bar for 40X magnification (H&E and KI67): 50 μ m. 
SEM (e) LX2 cells migrated within the decellularized sinusoidal space acquiring different morphologies: 
from a migratory flattened fibroblast-like cell phenotype, to a rounded shape; (i) HepG2 cells, showing 
an epithelioid phenotype, were spread diffusely and engrafted into the ECM scaffold; (m) Sk-HEP-1 cells 
repopulated the scaffold showing a mesenchymal-like phenotype. Scale bar SEM images = 10 μ m.
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the number of cells increased significantly (Fig. 7d) between 7, 14 and 21 days of culture (p < 0.05 and 
p < 0.001 at 14 days and 21 days, respectively). Scanning electron microscopy (SEM; Fig.  7e) further 
demonstrated that LX2 cells migrated within the decellularized sinusoidal space acquiring different mor-
phologies: from a flattened fibroblast-like cell phenotype, likely migratory, to a round-up shape probably 
indicating mitosis. Liver ECM cubes were also successfully repopulated with HepG2 cells, which rapidly 
engrafted and migrated through the scaffold (Fig. 7f). Repopulation with HepG2 cells was also charac-
terized by marked Ki67 positivity indicating cells proliferation (Fig. 7g). Accordingly, there was a marked 
increase in cell number between 7, 14 and 21 days (Fig. 7h; p < 0.05 and p < 0.004 at 14 days and 21 days, 
respectively). SEM showed that HepG2 cells, showing an epithelioid phenotype, were spread diffusely 
and engrafted into the ECM scaffold (Fig. 7i).
Metastatic Sk-Hep-1 cells rapidly repopulated the liver ECM cubes (Fig. 7j) showing a high prolifer-
ation rate (Fig. 7k) and a remarkable increase in total cell number between 7, 14 and 21 days (Fig. 7l; 
p < 0.003 and p < 0.008 at 14 and 21 days, respectively). Moreover, SEM images demonstrated that 
Sk-Hep-1 cells aggressively repopulated the scaffold showing a mesenchymal-like phenotype (Fig. 7m).
Discussion
The present paper describes our experience on the decellularization of human liver to generate human 
liver scaffolds. These results offer a key advance towards the use of healthy human livers unsuitable for 
liver transplantation for tissue engineering and ultimately aimed at functional organ replacement, disease 
modelling and assessment of drug efficacy/toxicity.
The first successful decellularization of a liver tissue, i.e. porcine, was reported in 2004 by Lin and 
Colleagues24. Repopulation of this scaffold with primary rat hepatocytes revealed a significantly higher 
albumin and urea synthesis by cells cultured within the scaffold when compared to monolayers of the 
primary hepatocytes cultured on collagen gels, thus suggesting a greater functional potential of cells cul-
tured in a 3D scaffold. Since 2004, several other reports have described the successful decellularization of 
rat, rabbit or pig livers14–17. More recently, Baptista and Colleagues have demonstrated the repopulation 
of decellularized pig liver with human hepatocyte progenitor cells or with foetal hepatocytes and foetal 
hepatic stellate cells for up to 13 days. This system showed active metabolism and albumin synthesis25.
The extensive exploitation of pig livers is related to both their wide availability and dimensions in 
a range compatible with the size of human liver. However, the ultrastructure of porcine liver differs 
significantly from that of human liver. Indeed, pig liver has well defined lobules outlined by connective 
tissue (portal to portal lining), which is absent in healthy human liver but present in fibrotic liver26 and 
it may not represent the ideal ECM for human liver tissue engineering. Thus, given the wide availability 
of donor human livers unsuitable for liver transplantation, it would be beneficial to make a step towards 
the optimal use of these organs for regenerative medicine. This approach towards the development of 
human tissue ECM scaffolds has been already proposed for kidney27, heart28 and lung29 in recent years.
The first important contribution emerging from the work herein presented is the description of a 
novel decellularization protocol which was designed in order to resolve many of the hurdles described in 
previously published protocols, with a special focus on the structure and biochemical features of human 
liver tissue. In particular, the application of decellularization protocols previously reported for the decel-
lularization of non-human livers and characterised by constant flow rate and anterograde perfusion30, 
repeatedly resulted in suboptimal results. Therefore, a novel protocol based on retrograde perfusion 
combined with two steps perfusion flow/rate was applied with the successful removal of immunogenic 
cellular materials, whilst maintaining the 3D architecture and essential extracellular matrix proteins. The 
resulting liver scaffold was robust, in that it could be easily handled without disintegration or rupture, 
maintaining its tissue flexibility.
The observation that collagen types I and IV, and fibronectin were present in bundles around the vas-
cular and biliary structures, portal triads, and central veins, as well as in the space of Disse, emphasises 
the preservation of liver architecture. This was further confirmed by SEM showing an extremely well 
preserved 3D-microanatomy of the portal tracts and liver lobules, and demonstrated the conservation of 
a three-dimensional meshwork of connective tissue fibres around the hepatocyte-free spaces.
Biocompatibility is an important issue to be clarified when proposing bio-technologies potentially 
leading to Advanced Therapy Medicinal Products31 (ATMP). In the case of a 3D human ECM scaffold the 
question is whether or not the ECM proteins present in the scaffold are able to evoke an immune response 
and rejection in non-matched recipient thus requiring continued immunosuppression32. The results 
obtained by implanting cubic fragments of human liver scaffold subcutaneously or intra-abdominally in 
immune competent mice show that there was no discernible immune reaction or rejection of the scaf-
fold. The implanted scaffold appeared to be incorporated into the host tissues with progressive host cell 
infiltration and arteriolar neovascularisation in both omental and subcutaneous implantations. This latter 
aspect is striking and deserves further investigation in order to define models of autologous repopulation 
by host-derived endothelial and other mesenchymal cells following implantation of a biological scaffold. 
Indeed, the model of re-creating autologous, i.e. host-derived, liver stroma, by implantation of a 3D ECM 
scaffold repopulated with functional hepatocytes derived from different potential sources, (e.g stem cells 
and iPSCs) represents an attractive line of research.
Finally, the repopulation of the ECM scaffold with different types of liver cells and the confirmation 
that the 3D structure enables and allows the efficient homing and targeting of cells to their correct 
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location is an indispensable step in the characterisation of the possible use of the ECM scaffolds for 
both regenerative medicine and disease modelling. To explore this aspect, three different cells lines were 
selected as representative prototypes to test scaffold repopulation: human hepatic stellate cells (LX2 cells) 
as typical liver-specific pericytes and main effectors of hepatic fibrogenesis33, HepG234 cells as well differ-
entiated neoplastic cells reproducing many of the features of normal hepatocytes, and Sk-Hep-135 cells, 
reproducing the features of an invasive metastatic adenocarcinoma. All three different cell types engrafted 
without difficulty into the cubic scaffold fragments with successful migration and cellular proliferation, 
although with different cell type-dependent dynamic and topographic features. These data confirm that 
the human liver bio-scaffold retains the essential characteristics necessary to provide homing of the cells 
to specific locations inside the scaffold.
Altogether the current results provide an innovative basis for further developments in the area of 
hepatic regenerative medicine through the use of human deceased donor livers that are unsuitable for 
whole organ transplantation. On this basis, the way to progress towards potential clinical applications 
should be directed at: a) the evaluation of different protocols for recellularization by employing perfusion 
bio-reactors allowing optimal cell homing when different cell types are employed, either singularly or 
together; b) proteomic studies to assess the preservation of ECM proteins and the presence of residual 
cellular materials; c) the assessment of the metabolic requirements and functionality of the bioengineered 
liver, and d) an estimation of the accuracy of different types of cell repopulation in reproducing 3D 
scenarios of liver pathophysiology fundamental for liver disease modelling as well as for drug toxicity/
efficacy testing. In this context, a key challenge will be represented by the re-endothelization of hepatic 
sinusoids and portal triad vasculature.
Methods
Source of human livers. The work described in this paper was performed on healthy human liv-
ers that were harvested for transplantation and then judged unsuitable because of prolonged graft cold 
ischaemic time, the presence of extra-hepatic malignancy or other important extra-hepatic co-morbidi-
ties in donors or recipients. Livers included in this study were defined “healthy” because of the absence 
of any degree of tissue fibrosis and fat accumulation by histological analysis. The study was approved by 
the UCL Royal Free BiobankEthical Review Committee (NRES Rec Reference: 11/WA/0077). Informed 
consent for research was confirmed via the NHSBT ODT organ retrieval pathway, and the project was 
also approved by the NHSBT Research Governance Committee. Donor livers were processed in accord-
ance with the UCL Royal Free Biobank protocols under the Research Tissue Bank Human Tissue Act 
licence, prior to use in research. Human livers obtained at the Royal Free London Foundation Trust were 
coordinated, received and recorded by the UCL Tissue Access for Patient Benefit organisation (TAPb) 
which links research activities between UCL Royal Free Biobank, the Royal Free Trust and UCL. TAPb 
has full governance in place for this purpose which has involved NHSBT ODT pathway, the Human 
Tissue Authority licencing, and the local Trust/UCL Research offices.
Surgery of human liver in preparation for the decellularization procedure. Human livers 
(n = 3) were either surgically processed in order to obtain the liver left lobes (n = 2) [374 g and 250 g, 
respectively] including segments 1, 2, 3 and 4 or retained as a whole liver (n = 1) [1, 774 Kg] with pre-
served vascular access.
Whole liver preparation: the donor liver was processed exactly as for liver transplantation; thereafter 
the upper caval cuff, reaching the atrial rim, was oversewn with a running double row of 3-0 prolene 
suture. The water tightness of the organ was proofed both by antegrade portal and retrograde hepatic 
venous perfusion under relative high pressure as produced by a 50 ml bladder syringe with PBS solution.
Segmental liver preparation of left lateral liver (S1 + S2 + S3 + S4): dissection is started at the hilar 
region with inspection, preparation, division and ligation of the hepatic artery (HA), of the portal vein 
(PV) and of the bile duct (BD). Segment 4 HA is preserved if originating from the right hepatic artery, 
forcing the division of the right HA distal to its bifurcation. The right hepatic vein is divided and the 
middle and left hepatic veins are preserved with the future left reduced size left liver. The line of paren-
chymal division is maintained to the left of the line of Cantlie in order to maintain the left portion of S4. 
The parenchyma is divided sharply with a knife for the liver capsule and subsequently with crush-clamp 
technique, performing meticulous hemo- and bilio-stasis. The parenchymal division is carried to the end, 
producing a left lateral liver extended to S4 and a right liver as non-functional unit. Finally, the upper 
caval cuff, reaching the atrial rim is oversewn with a running double run of 3-0 prolene suture.
Human livers were then frozen at − 80 °C for at least 24 h for the purposes of initial destruction of 
the various cellular compartments.
Decellularization Protocols of Whole Human Liver Lobe. The perfusion regime for the decellu-
larization of the liver left lobe is shown in Table1. The decellularization of the whole liver was achieved 
by repeating the procedure shown in Table  1 three times (the freezing/thawing step was performed 
just once). The following abbreviations were used: distilled Water (dH2O), TX100 (Triton X100), SDS 
(sodium dodecyl sulfate), A-A 5% (Antibiotic and Antimycotic), PAA (paracetic acid) and EtOH (etha-
nol) purchased from Sigma Aldrich.
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The initial flow rate for decellularization perfusion was 0.2–0.3 ml/min/g of liver. Subsequently, two 
phases of perfusion were adopted a) steeply increasing flow rate to compensate reduced resistance and 
b) stabilization of the flow rate as the decellularization proceeds. The two phases of flow rate are shown 
in Fig. 8. After decellularization, 125 mm3 cubic scaffold fragments (5 mm× 5 mm× 5 mm) were dissected 
by scalpel cleavage for further characterization and liver bioengineering in vitro.
Histology and immunostaining analysis. Samples were fixed for at least 24 hours in 10% neutral 
buffered formalin solution (pH 7.4) at RT. Tissue was embedded in paraffin and sectioned at 4 μ m. Prior 
to staining sections were dewaxed in xylene and rehydrated using graded industrial denatured alcohol 
(IDA).
Steps and Reagents
Days 1st 2nd 3rd 4th 5th
− 1 Thaw liver overnight at 4 °C
0 dH2O
0.025% Trypsin-
EDTA
1 dH2O 0.01% SDS 0.1% SDS 1% SDS
2 dH2O
0.025% Trypsin-
EDTA 1% SDS
3 dH2O 3% TX100
4 dH2O 3% TX100
5 dH2O 3% TX100
6 dH2O 3% TX100 1X PBS
7 dH2O
0.025% Trypsin-
EDTA
8 dH2O 1% SDS
9 dH2O 1% SDS
10 dH2O 1% SDS
11 dH2O 1% SDS
12 dH2O 1% SDS
13 dH2O PBS/AA 5% 3% TX100
14 dH2O PBS/AA 5% dH2O 0.1%PAA/4% EtOH 1X PBS sterile
Table 1.  Perfusion protocol. The decellularization of the whole human liver was achieved by repeating 
three times the procedure shown in the Table (the freezing/thawing step was performed just once). 
Abbreviations: dH2O (distilled water), TX100 (Triton X100), SDS (sodium dodecyl sulfate), A-A 5% 
(Antibiotic and Antimycotic), PAA (paracetic acid) and EtOH (ethanol).
Figure 8. Flow rate. The graph illustrates the increasing flow rate (x fold) over time starting with an 
initial flow rate of 0.2–0.3 ml/min/g of liver. The decellularization of a human liver left lobe (blue line) was 
achieved in 2 weeks, while the decellularization of a whole human liver (red line) was completed in 6 weeks.
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Histochemical stains: tissue sections were stained with Harris’s Haematoxylin and Eosin (H&E) 
(Leica, Germany), Picro-Sirius Red (SR) (Hopkin & Williams) (BDH Chemicals Ltd, Cellpath Ltd) and 
stains Miller’s Elastic stain with a Picro-Sirius red counter stain (VWR, Leica, Raymond A Lamb).
Immunocytochemistry: sections stained with Collagen I, III, IV, fibronectin and laminin were incu-
bated in 0.5% Trypsin (MP Biomedical)/0.5% Chymotrypsin (Sigma)/1% Calcium Chloride (BDH) in 
Tris buffered saline pH 7.6 (TBS) for 30 minutes at 37 °C. Sections stained with alpha-smooth muscle 
actin (SMA) were microwaved (640 W) for 20 minutes in 1L of Tris-EDTA buffer (10 mM Tris-base/1 mM 
EDTA solution, pH9.0) and sections for CD3 pressure cooked for 3 mins in sodium citrate buffer 
(10 mM Sodium Citrate, pH 6.0). Slides were then soaked in TBS with 0.04% Tween-20 (Sigma) for 
5 mins, blocked in peroxidase blocking solution (Novocastra) for 5 minutes, washed in TBS for 5 mins 
and then incubated for 1 hour in the following primary antibodies; collagen I (Rabbit pAb to coll1 
(ab34710), diluted 1:200; Abcam), collagen III (Rabbit pAB to coll3 (ab7778), diluted 1:500; Abcam), 
collagen IV (mouse mAb to coll4 (M0785), diluted 1:25; Dako), fibronectin (mouse mAb to fibronectin 
(MAB1937), diluted 1:100; Millipore), laminin (mouse mAb to laminin α 5-chain (MAB1924), diluted 
1:200; Millipore), alpha-Smooth Muscle Actin (mouse mAb to SMA, (M0851/1A4), diluted 1:500; Dako) 
and CD3 (rabbit pAb to CD3, (AO452), diluted 1:200; Dako). The slides were then placed for 25 minutes 
in NovolinkTM post primary (Novocastra), 25 mins in NovolinkTM polymer solution (Novocastra) and 
developed with NovolinkTM 3,3′ di-amino-benzidine (Novocastra) with a 5 minute wash in TBS with 
0.04% Tween-20 between each step. Slides were counterstained with Mayer’s Haematoxylin (Sigma) for 
3 min. All sections were dehydrated in graded IDA, cleared in xylene and were mounted with DPX 
(Leica biosystems); cover slipped and observed using a Zeiss Axioskop 40. Images were captured with 
an Axiocam IcC5 using Zeiss Axiovision (verison 4.8.2). All images were analysed and enhanced using 
Fiji v1.49d (ImageJ Jenkins server).
DNA quantification. To assess total DNA content within native tissue and acellular matrices, the 
DNeasy Blood and Tissue kit was used according to the manufacturer’s manual (Qiagen). Briefly, speci-
mens were digested with Proteinase K overnight. DNA samples were purified using buffers provided by 
the company and measured spectrophotometrically (Nanodrop, Thermo Scientific, US). Optical densities 
at 260 nm and 280 nm were used to estimate the purity and yield of nucleic acids.
Collagen quantification. The collagen content of native tissue and decellularized tissue was quanti-
fied using the total collagen assay kit according to the manufacturer’s manual (QuickZyme Biosciences, 
The Netherlands). Briefly, samples were hydrolysed in 6M HCl at 95 °C for 20 hours, the hydrolysates 
were mixed with a chromogen solution staining the hydroxyproline residues and color was developed at 
60 °C for 1 hour. The absorbance for each sample was determined at 555 nm using a FLUOstar Omega 
microplate reader (BMG labtech, Germany) and the collagen quantity was calculated by usage of a stand-
ard curve of pure collagen hydrolysates.
Elastin quantification. The elastin content of native and decellularized tissue was quantified using 
the FASTIN elastin assay (Biocolor, UK) according to the manufacturer’s instructions. Briefly, the samples 
were homogenized, and elastin was solubilized in 0.25 M oxalic acid. Two consecutive incubations were 
performed at 95 °C to ensure complete extraction of elastin. Extracts were incubated with 5,10,15,20-tetr
aphenyl-21H,23H-porphine tetrasulfonate (TPPS) dye, and absorbance was determined at 513 nm spec-
trophotometrically FLUOstar Omega microplate reader (BMG labtech, Germany). Elastin concentrations 
from a standard curve were used to calculate the elastin content of the tissue.
Scanning Electron Microscopy (SEM). Samples were fixed in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer and left for 24 hours at 4 °C. Following washing with 0.1 M phosphate buffer, samples were 
cut into segments of approximately 1 cm length and cryoprotected in 25% sucrose, 10% glycerol in 0.05 M 
PBS (pH 7.4) for 2 hours, then fast frozen in Nitrogen slush and fractured at approximately − 160 °C. 
Next, samples were then placed back into the cryoprotectant at room temperature and allowed to thaw. 
After washing in 0.1 M phosphate buffer (pH 7.4), the material was fixed in 1% OsO4 / 0.1 M phosphate 
buffer (pH 7.3) at 3 °C for 1½ hours and washed again in 0.1 M phosphate buffer (pH 7.4). After rinsing 
with dH2O, specimens were dehydrated in a graded ethanol-water series to 100% ethanol, critical point 
dried using CO2 and finally mounted on aluminum stubs using sticky carbon taps. The fractured material 
was mounted to present fractured surfaces across the parenchyma to the beam and coated with a thin 
layer of Au/Pd (approximately 2 nm thick) using a Gatan ion beam coater. Images were recorded with a 
7401 FEG scanning electron microscope (Jeol, USA).
Xenotransplantation in immunocompetent mice. All animal experiments were approved by the 
Home Office under the UK Animals and Scientific Procedures Act 1986 and in accordance with the 
guidelines of the Comparative Biology Unit, Biological Services University College London (UCL) under 
Project license 70/7100.
For biocompatibility studies, twelve male C57BL/6J mice, aged 3–4 weeks, were used. Human liver 
cubic scaffolds were surgically implanted either subcutaneously (n = 6) or into the omentum (n = 6). 
Following shaving the operating area, the skin was cleaned with 10% povidone iodine (Videne, Ecolab, 
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Leeds, UK) and 20% chlorhexidine gluconate (Hydrex pink, Ecolab, Leeds, UK). Isoflurane (2% with 
98% oxygen) was used to induce anesthesia. For subcutaneous implantation, a small incision (5 mm) was 
made between the shoulder blades and a subcutaneous tunnel was made by blunt dissection. The human 
liver cubic scaffold was inserted into the subcutaneous tunnel and the wound was closed with absorbable 
4-0 vicryl sutures. When applying an omental implantation, a small midline abdominal incision was 
made and the human liver cubic scaffold was folded with the omentum and was secured in place by 6-0 
vicryl sutures. The abdomen was closed in two layers. After 7 and 21 days, mice were euthanized and the 
implants along with the surrounding tissues were harvested and fixed in 10% formalin for histological 
and immunohistochemical evaluation.
Cell Culture. The LX2 cell line is a well-established hepatic stellate cell line that was generated by a 
spontaneous immortalization in low serum conditions30. Cells are cultured in Iscove’s Modified DMEM 
supplemented with 2 mM/L glutamine, 0.1 mM/L non-essential amino acids, 1.0 mM/L sodium pyruvate 
and 20% Foetal Bovine Serum (FBS). HepG2 and Sk-Hep-1 cells (ATCC® HTB-52™ ) are derived from 
a human hepatoblastoma and a human hepatocellular carcinoma, respectively. Both cell types were pur-
chased from ATCC (VA, USA) and cultured in Eagle’s Minimum Essential medium (EMEM), supple-
mented with Glutamax, 0.1 mM/L non-essential amino acids, 1.0 mM/L sodium pyruvate and 10% FBS. 
All cells were cultured under standard conditions in a humidified incubator under 5% CO2 and at 37 °C. 
Every 3 days the complete culture medium was changed and sub-confluent cells were trypsinized and 
passaged at a split ratio 1:3.
Repopulation and culture of engineered human liver. Human liver cubic scaffolds were kept 
overnight in complete medium [day -1]. Cells were re-suspended at a concentration of 2 million cells per 
50 μ l (2 × 106/50 μ L) per scaffold (n ≥ 12 per cell line). Cells were drawn up in a 0.5 ml insulin syringe 
and released drop by drop to finally cover the decellularized tissue. Seeded scaffolds were kept for 2 h in a 
humidified environment at 37 °C with 5% CO2 allowing cell attachment followed by addition of complete 
culture medium [day 0]. The culture medium was changed at day 1 and afterwards every 3 days. At days 
7, 14 and 21 following seeding, the scaffolds were placed in 10% formaldehyde and assessed by histology 
and immunohistochemistry or fixed in 2.5% glutaraldehyde for SEM analysis.
Statistical analysis. Results were expressed as mean ± s.d. All data was analysed with ANOVA or 
Student’s t-test. Two-talied p values less than 0.05 were considered statistically significant.
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